Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

HER2-targeted bispecific antibody ZW25 will be used in combination with other drugs for HER2-positive breast cancer and gastroesophageal adenocarcinoma.

The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.

The precision oncology startup is gearing up to enroll patients in its tissue-agnostic Phase I/II trial for its investigational new drug BDTX-189.

The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.

The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.

The NDA, based on data from a randomized Phase II trial, is for the use of tucatinib combined with trastuzumab and capecitabine for HER2-positive breast cancer patients.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.

Pages